Marc Began Biography and Net Worth

EVP of AxoGen

Mr. Began assumed the role of Executive Vice President and General Counsel in March of 2023. He brings more than 25 years of experience representing life science companies as in-house and external counsel. From June 2018 until its acquisition in December 2022 by Johnson and Johnson, Inc., he served as Executive Vice President, General Counsel and Secretary of Abiomed, Inc., a publicly traded med-tech company specializing in heart, lung and kidney recovery and was responsible for leading its legal, compliance and business development functions. While at Abiomed, he oversaw the acquisitions of new companies and new products. From August of 2017 until June of 2018, he was Vice President of Legal and Intellectual Property at Boehringer Ingelheim, a privately held pharmaceutical and biologics company, where he was responsible for medical device, pharmaceutical, and biologic legal and intellectual property issues. Before joining Boehringer Ingelheim, he held various positions of increasing responsibility over a 15-year period at Novo Nordisk, a publicly traded company specializing in metabolic and endocrinological diseases. Prior to becoming an in-house lawyer for Novo Nordisk, Mr. Began was in private practice at the law firms of Sullivan & Cromwell LLP and White & Case LLP in New York, where he handled a broad range of legal matters, including litigation, intellectual property, corporate transactions, regulatory and compliance for private and public companies. Mr. Began earned a Juris Doctor degree from Albany Law School at Union University and holds a Bachelor of Science degree in Mechanical Engineering from Rensselaer Polytechnic Institute.

What is Marc A. Began's net worth?: The estimated net worth of Marc A. Began is at least $1.10 million as of December 9th, 2025. Began owns 31,507 shares of AxoGen stock worth more than $1,103,060 as of February 3rd. This net worth estimate does not reflect any other assets that Began may own. Learn More about Marc A. Began's net worth.
How old is Marc A. Began?: Began is currently 56 years old. There are 3 older executives and no younger executives at AxoGen. The oldest executive at AxoGen is Ms. Karen Zaderej, Advisor, who is 62 years old. Learn More on Marc A. Began's age.
How do I contact Marc A. Began?: The corporate mailing address for Began and other AxoGen executives is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. AxoGen can also be reached via phone at (386) 462-6800 and via email at [email protected]. Learn More on Marc A. Began's contact information.
Has Marc A. Began been buying or selling shares of AxoGen?: Marc A. Began has not been actively trading shares of AxoGen during the last quarter. Most recently, Marc A. Began sold 9,278 shares of the business's stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $31.21, for a transaction totalling $289,566.38. Following the completion of the sale, the executive vice president now directly owns 31,507 shares of the company's stock, valued at $983,333.47. Learn More on Marc A. Began's trading history.
Who are AxoGen's active insiders?: AxoGen's insider roster includes Marc Began (EVP), P Burke (Director), Michael Dale (CEO), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Lindsey Hartley (CFO), John Johnson (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Paul Thomas (Director), Joseph Tyndall (Director), Kathy Weiler (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.
Are insiders buying or selling shares of AxoGen?: In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 475,453 shares worth more than $12,603,234.48. The most recent insider tranaction occured on December, 16th when Director Amy Mcbride Wendell sold 43,684 shares worth more than $1,280,378.04. Insiders at AxoGen own 2.8% of the company. Learn More about insider trades at AxoGen.
Information on this page was last updated on 12/16/2025.

Marc A. Began Insider Trading History at AxoGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/9/2025	Sell	9,278	$31.21	$289,566.38	31,507

Marc A. Began Buying and Selling Activity at AxoGen

AxoGen Company Overview

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Today's Range

Now: $35.01

$34.21

$35.93

50 Day Range

MA: $31.65

$27.69

$35.02

2 Week Range

Now: $35.01

$9.22

$36.00

Volume

499,774 shs

Average Volume

1,040,263 shs

Market Capitalization

$1.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Marc Began Biography and Net Worth

What is Marc A. Began's net worth?

How old is Marc A. Began?

How do I contact Marc A. Began?

Has Marc A. Began been buying or selling shares of AxoGen?

Who are AxoGen's active insiders?

Are insiders buying or selling shares of AxoGen?